JP2015526442A5 - - Google Patents

Download PDF

Info

Publication number
JP2015526442A5
JP2015526442A5 JP2015527567A JP2015527567A JP2015526442A5 JP 2015526442 A5 JP2015526442 A5 JP 2015526442A5 JP 2015527567 A JP2015527567 A JP 2015527567A JP 2015527567 A JP2015527567 A JP 2015527567A JP 2015526442 A5 JP2015526442 A5 JP 2015526442A5
Authority
JP
Japan
Prior art keywords
fluoro
indazol
chloro
acid
benzyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2015527567A
Other languages
English (en)
Japanese (ja)
Other versions
JP6411345B2 (ja
JP2015526442A (ja
Filing date
Publication date
Priority claimed from PCT/CN2012/080134 external-priority patent/WO2014026329A1/en
Application filed filed Critical
Publication of JP2015526442A publication Critical patent/JP2015526442A/ja
Publication of JP2015526442A5 publication Critical patent/JP2015526442A5/ja
Application granted granted Critical
Publication of JP6411345B2 publication Critical patent/JP6411345B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2015527567A 2012-08-15 2013-08-14 RORγT阻害剤としてのN−アルキル化インドールおよびインダゾール化合物およびそれらの使用 Expired - Fee Related JP6411345B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/CN2012/080134 WO2014026329A1 (en) 2012-08-15 2012-08-15 N-alkylated indole and indazole compounds as rorgammat inhibitors and uses thereof
CNPCT/CN2012/080134 2012-08-15
PCT/US2013/054893 WO2014028591A2 (en) 2012-08-15 2013-08-14 N-ALKYLATED INDOLE AND INDAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF

Publications (3)

Publication Number Publication Date
JP2015526442A JP2015526442A (ja) 2015-09-10
JP2015526442A5 true JP2015526442A5 (https=) 2016-09-23
JP6411345B2 JP6411345B2 (ja) 2018-10-24

Family

ID=50101187

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015527567A Expired - Fee Related JP6411345B2 (ja) 2012-08-15 2013-08-14 RORγT阻害剤としてのN−アルキル化インドールおよびインダゾール化合物およびそれらの使用

Country Status (9)

Country Link
US (1) US9556168B2 (https=)
EP (1) EP2884977B1 (https=)
JP (1) JP6411345B2 (https=)
KR (1) KR20150041659A (https=)
AU (1) AU2013302727A1 (https=)
BR (1) BR112015003397A2 (https=)
CA (1) CA2881693A1 (https=)
RU (1) RU2015108935A (https=)
WO (2) WO2014026329A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026328A1 (en) * 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof
EP3102576B8 (en) 2014-02-03 2019-06-19 Vitae Pharmaceuticals, LLC Dihydropyrrolopyridine inhibitors of ror-gamma
JP2017507950A (ja) 2014-02-27 2017-03-23 リセラ・コーポレイションLycera Corporation レチノイン酸受容体関連オーファン受容体ガンマのアゴニストを使用する養子細胞療法及び関連治療方法
US9896441B2 (en) 2014-05-05 2018-02-20 Lycera Corporation Tetrahydroquinoline sulfonamide and related compounds for use as agonists of RORγ and the treatment of disease
JP6523337B2 (ja) 2014-05-05 2019-05-29 リセラ・コーポレイションLycera Corporation RORγのアゴニストとしての使用及び疾患治療のためのベンゼンスルホンアミド及び関連化合物
PT3207043T (pt) 2014-10-14 2019-03-25 Vitae Pharmaceuticals Llc Inibidores de di-hidropirrolopiridina de ror-gama
GB201419015D0 (en) 2014-10-24 2014-12-10 Orca Pharmaceuticals Ltd Compounds
US9845308B2 (en) 2014-11-05 2017-12-19 Vitae Pharmaceuticals, Inc. Isoindoline inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
EP3242878B1 (en) 2015-01-08 2020-10-14 Impetis Biosciences Ltd. Bicyclic compounds, compositions and medicinal applications thereof
US10385036B2 (en) 2015-01-30 2019-08-20 Pfizer Inc. Sulfonamide-substituted indole modulators of RORC2 and methods of use thereof
EP3256450B1 (en) * 2015-02-11 2020-12-02 Merck Sharp & Dohme Corp. Substituted pyrazole compounds as ror-gamma-t inhibitors and uses thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016145298A1 (en) 2015-03-12 2016-09-15 The Regents Of The University Of California METHODS FOR TREATING CANCER WITH RORgamma INHIBITORS
JP2018515491A (ja) 2015-05-05 2018-06-14 リセラ・コーポレイションLycera Corporation RORγの作動薬及び疾患の療法として使用するジヒドロ−2H−ベンゾ[b][1,4]オキサジンスルホンアミド及び関連化合物
KR20180025894A (ko) 2015-06-11 2018-03-09 라이세라 코퍼레이션 Rory의 작용제로서 사용하기 위한 아릴 디히드로-2h-벤조[b][1,4]옥사진 술폰아미드 및 관련 화합물 및 질환의 치료
WO2017024018A1 (en) 2015-08-05 2017-02-09 Vitae Pharmaceuticals, Inc. Modulators of ror-gamma
CN108137585B (zh) * 2015-09-21 2021-10-22 普莱希科公司 杂环化合物及其应用
AU2016344118A1 (en) 2015-10-27 2018-05-10 Merck Sharp & Dohme Corp. Heteroaryl substituted benzoic acids as rorgammat inhibitors and uses thereof
RU2018117503A (ru) 2015-10-27 2019-11-28 Мерк Шарп И Доум Корп. ЗАМЕЩЕННЫЕ ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORγТ И ИХ ПРИМЕНЕНИЕ
WO2017075178A1 (en) 2015-10-27 2017-05-04 Merck Sharp & Dohme Corp. SUBSTITUTED BICYCLIC PYRAZOLE COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
US11008340B2 (en) 2015-11-20 2021-05-18 Vitae Pharmaceuticals, Llc Modulators of ROR-gamma
US10662187B2 (en) * 2016-01-21 2020-05-26 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Bruton's tyrosine kinase inhibitors
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ROR-γ調節劑
US9481674B1 (en) 2016-06-10 2016-11-01 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
AU2017360939B2 (en) 2016-11-18 2022-03-03 Merck Sharp & Dohme Corp. Indazole derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2
JP7090639B2 (ja) 2017-04-11 2022-06-24 サンシャイン・レイク・ファーマ・カンパニー・リミテッド フッ素置換されたインダゾール化合物及びその使用
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
JP2020528904A (ja) 2017-07-24 2020-10-01 ヴァイティー ファーマシューティカルズ,エルエルシー RORγの阻害剤
CN108586432B (zh) * 2018-05-31 2020-08-25 温州医科大学 一种3-(吲哚-5-基)-吲唑衍生物及其应用

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4670447A (en) 1983-08-22 1987-06-02 Hoechst-Roussel Pharmaceuticals Inc. Antipsychotic 3-(piperidinyl)- and 3-(pyrrolidinyl)-1H-indazoles
PT95899A (pt) * 1989-11-17 1991-09-13 Glaxo Group Ltd Processo para a preparacao de derivados indole
WO1995027202A1 (en) * 1994-03-30 1995-10-12 Ciba-Geigy Ag Screening method using the rzr receptor family
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US6133290A (en) 1998-07-31 2000-10-17 Eli Lilly And Company 5-HT1F agonists
US6716452B1 (en) * 2000-08-22 2004-04-06 New River Pharmaceuticals Inc. Active agent delivery systems and methods for protecting and administering active agents
US6387942B2 (en) * 2000-06-19 2002-05-14 Yung Shin Pharmaceutical Ind. Co. Ltd Method of treating disorders related to protease-activated receptors-induced cell activation
GB0117577D0 (en) 2001-02-16 2001-09-12 Aventis Pharm Prod Inc Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D receptor ligands
US7355042B2 (en) 2001-10-16 2008-04-08 Hypnion, Inc. Treatment of CNS disorders using CNS target modulators
TW200539874A (en) * 2004-03-15 2005-12-16 Yung Shin Pharmaceutical Ind Preferential inhibition of release of pro-inflammatory cytokines
JP2008509138A (ja) 2004-08-03 2008-03-27 ワイス 心臓血管疾患の治療に有用なインダゾール類
US7605168B2 (en) 2004-09-03 2009-10-20 Plexxikon, Inc. PDE4B inhibitors
MX2007003336A (es) * 2004-09-21 2007-06-05 Athersys Inc Acidos aceticos de indol que muestran antagonismo de receptor crth2 y usos de los mismos.
CN100516049C (zh) * 2004-11-16 2009-07-22 永信药品工业股份有限公司 抗血管生成药n2-(取代的芳基甲基)-3-(取代的苯基)吲唑的合成
EP1828180A4 (en) 2004-12-08 2010-09-15 Glaxosmithkline Llc 1H-pyrrolo [2,3-BETA] PYRIDINE
CA2637531A1 (en) 2006-02-17 2007-08-30 Memory Pharmaceuticals Corporation Compounds having 5-ht6 receptor affinity
JP4675801B2 (ja) 2006-03-06 2011-04-27 日本メナード化粧品株式会社 Ror活性化剤
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
MX2009011210A (es) 2007-04-16 2009-10-30 Abbott Lab Inhibidores de mcl1 de indol 7-no sustituido.
GB0708141D0 (en) 2007-04-26 2007-06-06 Syngenta Participations Ag Improvements in or relating to organic compounds
AR067326A1 (es) 2007-05-11 2009-10-07 Novartis Ag Imidazopiridinas y pirrolo -pirimidinas sustituidas como inhibidores de cinasa de lipido
AR068046A1 (es) 2007-06-05 2009-11-04 Schering Corp Derivados policiclicos de indazol y su uso como inhibidores de erk para el tratamiento del cancer
US20100317863A1 (en) 2007-07-25 2010-12-16 Boehringer Ingelheim International Gmbh Glucocorticoid Mimetics, Methods of Making Them, Pharmaceutical Compositions and Uses Thereof
US8703778B2 (en) * 2008-09-26 2014-04-22 Intellikine Llc Heterocyclic kinase inhibitors
EP2181710A1 (en) 2008-10-28 2010-05-05 Phenex Pharmaceuticals AG Ligands for modulation of orphan receptor-gamma (NR1F3) activity
WO2010050837A1 (ru) 2008-10-28 2010-05-06 Haskin Lev Yakovlevich Ветроэнергетическая установка
CA2744498C (en) 2008-11-25 2017-10-24 University Of Rochester Mlk inhibitors and methods of use
WO2010150837A1 (ja) 2009-06-25 2010-12-29 第一三共株式会社 インドリン誘導体
WO2011014775A1 (en) 2009-07-31 2011-02-03 The Brigham And Women's Hospital, Inc. Modulation of sgk1 expression in th17 cells to modulate th17-mediated immune responses
WO2011055270A1 (en) * 2009-11-04 2011-05-12 Wyeth Llc Indole based receptor crth2 antagonists
JP2013514385A (ja) * 2009-12-18 2013-04-25 ヤンセン ファーマシューティカ エヌ.ベー. エストロゲン関連受容体αモジュレーターとしての置換アミノチアゾロンインダゾール
US9260382B2 (en) 2010-02-16 2016-02-16 Uwm Research Foundation Methods of reducing virulence in bacteria
WO2011146313A1 (en) * 2010-05-19 2011-11-24 The University Of North Carolina At Chapel Hill Pyrazolopyrimidine compounds for the treatment of cancer
CA2816753A1 (en) * 2010-11-08 2012-05-18 Lycera Corporation N- sulfonylated tetrahydroquinolines and related bicyclic compounds inhibition of rory activity and the treatment of diseases
RU2620376C2 (ru) 2010-12-22 2017-05-25 Людвиг-Максимилианс-Университэт Мюнхен Цинкорганические комплексы, способы их получения и применение
EP2487159A1 (en) 2011-02-11 2012-08-15 MSD Oss B.V. RorgammaT inhibitors
JP2014166961A (ja) 2011-06-20 2014-09-11 Dainippon Sumitomo Pharma Co Ltd 新規インダゾール誘導体
WO2014026330A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF
WO2014026327A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 4-heteroaryl substituted benzoic acid compounds as rorgammat inhibitors and uses thereof
WO2014026328A1 (en) 2012-08-15 2014-02-20 Merck Sharp & Dohme Corp. 3-cyclohexenyl substituted indole and indazole compounds as rorgammat inhibitors and uses thereof

Similar Documents

Publication Publication Date Title
JP2015526442A5 (https=)
RU2015108935A (ru) СОЕДИНЕНИЯ N-АЛКИЛИРОВАННЫХ ИНДОЛОВ И ИНДАЗОЛОВ В КАЧЕСТВЕ ИНГИБИТОРОВ RORgammaT И СПОСОБЫ ИХ ПРИМЕНЕНИЯ
JP2014509316A5 (https=)
JP6170040B2 (ja) ピルフェニドン及び選択された患者における抗線維化療法
JP2018519323A5 (https=)
JP2013543896A5 (https=)
JP2015526441A5 (https=)
SI2989100T1 (en) NAFTIRIDINE DERIVATIVES USED AS ANTAGONISTS INTEGRITY OF ALFA-V-BETA-6
JP2014526492A5 (https=)
JP2015500326A5 (https=)
JP2008513499A5 (https=)
RU2009104340A (ru) Производные [4,5']бипиримидинил-6,4'-диамина в качестве ингибиторов протеинкиназы
JP2016512825A5 (https=)
ME01462B (me) Vinilindazolilna jedinjenja"
RU2015108898A (ru) 3-ЦИКЛОГЕКСЕНИЛ И ЦИКЛОГЕКСИЛ ЗАМЕЩЕННЫЕ ИНДОЛЬНЫЕ И ИНДАЗОЛЬНЫЕ СОЕДИНЕНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ RORгаммаТ И ИХ ПРИМЕНЕНИЯ
KR20110117658A (ko) 메토트렉세이트 및 dhodh 억제제를 포함하는 조합물
HRP20151405T1 (hr) Novi supstituirani kinolinski spojevi kao inhibitori reduktaze s-nitrosoglutationa
NZ603463A (en) Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012515787A5 (https=)
ZA200606636B (en) Therapeutic combinations of atypical antipsychotic with corticotropin releasing factor antagonists
US20160024096A1 (en) Methods and compositions for inhibition of bromodomain-containing proteins
JP2004524301A5 (https=)
JP2011524896A5 (https=)
JP2007509117A5 (https=)
JP2016500068A5 (https=)